Drug Trial Radar · NCT00299689
Phase II Trial of Ontak With Metastatic Melanoma
Last checked: Nov 20, 2026Latest source record: Sep 5, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
69
Actual
Start
Mar 2006
Primary completion
Jan 2010
Study completion Jan 2010
Sponsor
- Lead sponsor
- James Graham Brown Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Louisville
- First posted
- Mar 7, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether ONTAK is an effective treatment in patients with Stage IV Melanoma
Conditions
- Malignant Melanoma
Interventions
Denileukin diftitoxDrug
12 mcg/kg IV (in vein) over 30 minutes on days 1 through 4 of each 21 day cycle for 4 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Positive Response Defined as Clinical Complete Response, Partial Response or Stable Disease (Persisting for at Least 4 Weeks) as Measure by Modified RECIST CriteriaTime frame: 2 weeks after completion of second cycle
Locations
1 site in 1 country. Site status is shown where the registry gives one.
James Graham Brown Cancer Center, Univ. of Louisville
Louisville, Kentucky
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.